The International Myeloma Foundation (IMF) and the International Myeloma Working Group (IMWG) are proud to announce the recipients of this year’s Robert A. Kyle Achievement Award and Brian G.M. Durie Outstanding Achievement Award. globenewswire.com/news-release/2…

Congratulations to Shaji Kumar on being the 23rd recipient of prestigious Dr. Robert Kyle Lifetime Achievement Award. He joins the who's who of #Myeloma , including Dr. Kyle (2002) & Drs. Barlogie, Anderson, Harousseau, Palumbo, Vincent Rajkumar, and many others).
globenewswire.com/news-release/2…

Audience cheers for Dr. Shaji Kumar, my friend and colleague Mayo Clinic — we announced that he will be receiving the Robert A. Kyle Lifetime Achievement Award this evening at the IIMWG summit in Madrid.

Congrats Shaji Kumar
Mayo Myeloma

HAPPENING NOW: The IMF brings together 100 of the greatest minds in myeloma each year at the #IMFIMWG Summit. The mission is clear: to cure #myeloma . Yelak Biru Vincent Rajkumar Brian G.M. Durie Joseph Mikhael

Luciano J. Costa, MD, PhD, on Multiple Myeloma: Subgroup Analysis of CARTITUDE-4 on Ciltacabtagene Autoleucel ascopost.com/videos/2024-as… #mmsm #MultipleMyeloma #hematology #ASCO24 UAB Luciano J Costa

Challenges and opportunities in the assessment of measurable residual disease in multiple myeloma [Jul 31, 2019] Susan Bal Weaver R. Frank Cornell, MD, MS Luciano J Costa BJH ow.ly/8GqV30q1iQ1 #mmMRD #mmsm

Hematologist at #ASCO24 😂😂😂

Myeloma star Professor Dr. Suzanne Trudel Princess Margaret Cancer Centre rocks it at #ASCO24 - Belantamab practice changing positive phase 3 trial - simultaneous NEJM publication

🇧🇷Proud seeing or dear ⁦VaniaHungria⁩ as First author in NEJM. Along with ⁦marivi mateos⁩, women led NEJM publication.Unfortunately not routine. Congratulations!!Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma nejm.org/doi/full/10.10…

Important and one of very few datasets on 2nd and 3rd line Rx for patients with upfront dara exposure. Thanks Thanos Dimopoulos for pointing it out.

Just out: International Myeloma Working Group guidelines CAR-T cell treatment in myeloma.

For Limited time: Link to Free copy & more in thread! The Lancet Oncology Yi Lin Tom Martin Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Chng Wee Joo Luciano J Costa Ben Derman marivi mateos Joseph Mikhael et al
thelancet.com/journals/lanon…

Consensus guidelines and recommendations for the management and response assessment of CAR T-cell therapy in RRMM: a report from the International Myeloma Working Group Immunotherapy Committee - ScienceDirect sciencedirect.com/science/articl…

#ASCO24 Cilta-cel vs standard of care in patients with functional HRMM (PD within 18 months of 1st line): CARTITUDE-4 subgroup analysis . N=79, better outcomes with cita cel vs. SOC as shown in the table meetings.asco.org/abstracts-pres… #mmsm #bmtsm Luciano J Costa marivi mateos

Luciano J Costa Thanks very much for Luciano. With MRD as an early endpoint for accelerated approval in myeloma, patients will get access to new drugs much faster. Instead of 12 years, it can take 3 years to develop new drugs in newly diagnosed myeloma. It will allow us to develop a cure! #mmsm

EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical endpoint for multiple myeloma ashpublications.org/blood/article/…

Congratulations C. Ola Landgren, M.D. and team.

Drug Class Refractoriness, Not Number of Prior Lines of Therapy (LOT), Properly Classify Pts w/ Relapsed / Refractory Multiple Myeloma (RRMM) Receiving Contemporary Regimens [Dec 12, 2022] Luciano J Costa et al. Abst 4530 #ASH22
ash.confex.com/ash/2022/webpr… #mmsm #ClinicalTrials #caxtx